Alto Neuroscience (NYSE:ANRO) Raised to “Strong-Buy” at Chardan Capital

Alto Neuroscience (NYSE:ANRO) was upgraded by research analysts at Chardan Capital to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

Other research analysts have also issued reports about the stock. BTIG Research assumed coverage on shares of Alto Neuroscience in a research report on Monday. They set a “buy” rating and a $27.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, October 8th. Jefferies Financial Group upped their target price on Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. HC Wainwright lifted their price target on Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 24th. Finally, Robert W. Baird upped their price objective on shares of Alto Neuroscience from $16.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $23.83.

Alto Neuroscience Stock Down 8.7%

ANRO stock opened at $14.19 on Wednesday. The stock has a 50-day simple moving average of $8.58 and a two-hundred day simple moving average of $4.85. Alto Neuroscience has a twelve month low of $1.60 and a twelve month high of $16.49. The firm has a market capitalization of $440.88 million, a PE ratio of -6.20 and a beta of 2.90. The company has a quick ratio of 15.42, a current ratio of 15.42 and a debt-to-equity ratio of 0.20.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14. On average, equities analysts predict that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors have recently made changes to their positions in the business. SCS Capital Management LLC purchased a new position in Alto Neuroscience in the 1st quarter worth $144,000. Nuveen LLC bought a new position in shares of Alto Neuroscience during the first quarter valued at about $302,000. Peapod Lane Capital LLC purchased a new position in shares of Alto Neuroscience in the second quarter worth about $613,000. AWM Investment Company Inc. increased its holdings in shares of Alto Neuroscience by 31.1% in the first quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock worth $1,948,000 after buying an additional 214,153 shares during the period. Finally, Citizens Financial Group Inc. RI bought a new stake in shares of Alto Neuroscience in the 1st quarter valued at about $83,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.